Clopidogrel hypersensitivity: clinical challenges and options for management.

Area of Science:

• Cardiology
• Clinical Pharmacology
• Allergy and Immunology

Background:

• Clopidogrel is widely prescribed, but hypersensitivity affects up to 6% of patients, often causing rashes.
• Discontinuing clopidogrel prematurely after stenting increases risks of stent thrombosis, myocardial infarction, and death.
• Current desensitization protocols often require medication withdrawal, posing risks for recent stent recipients.

Purpose of the Study:

• To evaluate a novel clopidogrel desensitization protocol for hypersensitive patients.
• To assess the safety and efficacy of treating clopidogrel hypersensitivity without interrupting therapy.
• To explore an alternative management strategy for patients with clopidogrel hypersensitivity and recent stent placement.

Main Methods:

• A clinical approach involving short-course corticosteroids and antihistamines was employed.
• Patients continued clopidogrel therapy throughout the desensitization process.
• Physiologic tolerance to clopidogrel was induced while maintaining continuous medication.

Main Results:

• Successful treatment of clopidogrel hypersensitivity was achieved in clinical practice.
• The protocol allowed continuous clopidogrel administration, avoiding hazardous drug interruption.
• This method enables the development of tolerance without compromising antiplatelet therapy.

Conclusions:

• Clopidogrel hypersensitivity can be managed effectively without discontinuing the medication.
• Short-course corticosteroids and antihistamines facilitate tolerance induction in hypersensitive patients.
• This strategy is particularly valuable for patients with recent coronary stent placement, mitigating risks associated with therapy interruption.